Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab rezatecan + retlirafusp alfa + pertuzumab
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Trastuzumab rezatecan + retlirafusp alfa + pertuzumab is an investigational combination regimen being evaluated for the neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. The regimen consists of three distinct biologic agents: **trastuzumab rezatecan** (SHR-A1811), a HER2-targeted antibody-drug conjugate (ADC) featuring a trastuzumab-based antibody linked to a topoisomerase I inhibitor payload; **retlirafusp alfa** (SHR-1701), a bifunctional fusion protein designed to simultaneously block the PD-L1 and TGF-β pathways to enhance anti-tumor immunity; and **pertuzumab**, a monoclonal antibody that inhibits HER2 dimerization. This combination aims to provide comprehensive HER2 blockade while leveraging immune checkpoint inhibition and TGF-β signaling modulation to overcome resistance and improve pathological complete response (pCR) rates in the pre-surgical setting.
- Other names
- SHR-A1811 + SHR-1701 + pertuzumab biosimilar
02
Targets
TOP1 (DNA Topoisomerase I)HER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)CD274 (Programmed cell death protein 1 ligand 1)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on trastuzumab rezatecan + retlirafusp alfa + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab rezatecan + retlirafusp alfa + pertuzumab.